{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:24:32Z","timestamp":1748539472427,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous group of hematological malignancies involving T or NK cells. PTCLs are generally associated with an aggressive course and poor prognosis. Pralatrexate (PDX) is the first FDA-approved agent for the treatment of refractory\/recurrent PTCL. It has single-agent activity against PTCLs; however, oral mucositis represents dose-limiting toxicity in clinical practice. We report on the case of a patient administered with modified THP-COP therapy (pirarubicin [tetrahydropyranyl adriamycin], cyclophosphamide, and prednisone), who had bone or bone marrow as the primary lesion, which was treated successfully with PDX for an extended period of 1 year, with prophylactic use of leucovorin for oral mucositis. The maintenance dose of PDX was 30 mg\/m&lt;sup&gt;2&lt;\/sup&gt; IV, over 3 consecutive weeks dosing with a 1-week rest period due to bone marrow suppression. The patient also received leucovorin 5 mg PO 3 times daily from days 2 to 6 after each PDX administration. Disease activity was well controlled, stable, and no oral mucositis was observed over the course of treatment.<\/jats:p>","DOI":"10.1159\/000501070","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T21:00:44Z","timestamp":1563310844000},"page":"529-536","source":"Crossref","is-referenced-by-count":6,"title":["Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin"],"prefix":"10.1159","volume":"12","author":[{"given":"Koichi","family":"Kitazume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Akagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachie","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02207.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.853"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.7524"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2144"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0524"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.9024"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13340"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1306642"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-1214"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky038"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.779688"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.020"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/501070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/501070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:43:52Z","timestamp":1745426632000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000501070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,4]]}},"URL":"https:\/\/doi.org\/10.1159\/000501070","archive":["Portico"],"relation":{},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2019,7,16]]}}}